Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azithromycin + ciprofloxacin
- Development stage
- Phase 4
- Lead developer
- CHU de Québec-Université Laval
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Azithromycin + ciprofloxacin is a combination antibiotic regimen investigated by CHU de Quebec-Universite Laval for the periodical presumptive treatment (PPT) of sexually transmitted infections. This specific intervention was studied in a Phase 3 cluster-randomized trial (NCT00115388) to evaluate its impact on the prevalence of *Neisseria gonorrhoeae* and *Chlamydia trachomatis* among female sex workers in West Africa. Azithromycin, a macrolide antibiotic, inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Ciprofloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA replication by targeting DNA gyrase and topoisomerase IV. The trial utilized a monthly dosing schedule where azithromycin (1g) and ciprofloxacin (500mg) were administered in alternating months to reduce the burden of infection and secondary HIV transmission.
- Other names
- azithromycin and ciprofloxacin
02
Targets
Bacterial 50S ribosomal subunitGyrase-DNA complex (Bacterial DNA gyrase and topoisomerase IV cleaved DNA-enzyme complex)Topo IV-DCC (Bacterial topoisomerase IV–DNA cleavage complex)Topo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on azithromycin + ciprofloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azithromycin + ciprofloxacin.